에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Fear and Greed

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NFLX

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

CNN 머니 공포·탐욕 지수는 수요일(16일) &#39;극도의 공포&#39; 영역에 머물렀지만 전반적인 공포 수준이 더 상승한 것으로 나타났다.수요일 미국 증시는 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승 및 성장 둔화와 연결시키면서 연준이 시장 손실을 완화할 의사가 없음을 분명히 한 후 다우존스 지수가 장중 약 700포인트 하락하는 등 하락세로 마감했다.

엔비디아·AMD 급락으로 나스닥 3% 하락: 탐욕 지수는 &#39;극도의 공포&#39; 영역 유지

wall street, mercados estadounidenses

Equities

Government

Large Cap

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

FANG

JBHT

KLAC

PLTR

수요일(16일) 오후 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승과 성장 둔화에 연결시키면서 연준이 시장 손실을 완화할 의사가 없음을 분명히 한 후 위험심리는 급격한 타격을 입었다.

파월 의장, &#39;연준 풋&#39; 기대 일축···미국 증시 하락, 금 상승세 확대

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

CNN 머니 공포·탐욕 지수는 전반적인 공포 수준이 증가했음을 보여 주었고, 지수는 화요일에 &#34;극단적 공포&#34; 영역에 머물렀다.화요일(15일) 미국 증시는 하락세로 마감했고, 특히 다우존스 지수는 투자자들이 최근 실적 보고서를 평가하는 동안 세션 중 150포인트 이상 하락했다.

시티·뱅크오브아메리카 수익 예상치 상회, 다우 150포인트 이상 하락: 탐욕 지수 &#39;극단적 공포&#39; 영역 유지

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77%, but in the past year, increased by 22.07%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_0.png" alt="Past Year Chart" />

<h3>How Does Abbott Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 59.36 in the Health Care Equipment &amp; Supplies industry, Abbott Laboratories Inc. has a lower P/E ratio of 16.87. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Abbott Laboratories Inc's Price Over Earnings

<ul>
<li>Long-term data from the Volt&nbsp;CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt&#x2122; PFA System</li>
<li>The 12-month results of the Volt&nbsp;CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System</li>
<li>The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting</li>
</ul>

Reported Saturday, Abbott Presents New Volt PFA System Data Highlighting Outstanding Long-Term Safety And Freedom From Arrhythmia At 12 Months

<ul>
<li>Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker</li>
<li>Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead</li>
<li>Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm</li>
</ul>

Reported Sunday, Abbott's AVEIR CSP Study Demonstrates First Successful Leadless Conduction System Pacing In Left Bundle Branch Area

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$52.0K</td>
<td>100</td>
<td>4.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$33.3K</td>
<td>3.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$134.3K</td>
<td>992</td>
<td>550</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$17.50</td>
<td>$26.6K</td>
<td>20</td>
<td>401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$780.00</td>
<td>$25.9K</td>
<td>1.0K</td>
<td>384</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$25.0K</td>
<td>4.4K</td>
<td>262</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>897</td>
<td>233</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$70.00</td>
<td>$61.9K</td>
<td>336</td>
<td>39</td>
</tr>
<tr>
<td>MTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1180.00</td>
<td>$58.8K</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 100 contract(s) at a $450.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 100 open contracts at this strike prior to today, and today 4332 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option sweep that happens to be bullish, expiring in 273 day(s) on January 16, 2026. This event was a transfer of 34 contract(s) at a $50.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $980.0 per contract. There were 3960 open contracts at this strike prior to today, and today 1145 contract(s) were bought and sold. 
• For BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we notice a call option sweep that happens to be bearish, expiring in 28 day(s) on May 16, 2025. This event was a transfer of 363 contract(s) at a $105.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $134.3K, with a price of $370.0 per contract. There were 992 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we observe a put option trade with bearish sentiment. It expires in 28 day(s) on May 16, 2025. Parties traded 140 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $190.0 per contract. There were 20 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on April 17, 2025. This event was a transfer of 4 contract(s) at a $780.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $6480.0 per contract. There were 1032 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• Regarding SLNO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), we observe a call option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 50 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 4483 open contracts at this strike prior to today, and today 262 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 637 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $1050.0 per contract. There were 897 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a put option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 38 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $61.9K, with a price of $1630.0 per contract. There were 336 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold. 
• Regarding MTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), we observe a call option trade with bearish sentiment. It expires in 182 day(s) on October 17, 2025. Parties traded 12 contract(s) at a $1180.00 strike. The total cost received by the writing party (or parties) was $58.8K, with a price of $4900.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option trade that happens to be neutral, expiring in 336 day(s) on March 20, 2026. This event was a transfer of 5 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $5814.0 per contract. There were 10 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BHVN

BNTX

SLNO

SRPT

10 Health Care Stocks Whale Activity In Today's Session

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $132 to $142.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $142

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $133 to $145.

Reiteration

Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $145

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $140 to $145.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $136 to $147.

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $147

Morgan Stanley analyst David Lewis maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Equal-Weight and raises the price target from $117 to $127.

Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $127

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/abt/earnings">adjusted EPS results</a> on Wednesday.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.
These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.
<ul>
<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>
<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>
<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png" alt="" class="wp-image-877000" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44866413/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $158 to $159.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $159

11 analysts have shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.82, a high estimate of $160.00, and a low estimate of $135.00. This upward trend is apparent, with the current average reflecting a 5.92% increase from the previous average price target of $136.73.
<img src="https://www.benzinga.com/files/images/story/2025/1744898414_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Abbott Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $145.00&#x7C;$135.00 &#x7C; 
&#x7C;Matthew Taylor &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $137.00&#x7C;$135.00 &#x7C; 
&#x7C;Travis Steed &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $150.00&#x7C;$133.00 &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $160.00&#x7C;$135.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $154.00&#x7C;$138.00 &#x7C; 
&#x7C;Matt Miksic &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $158.00&#x7C;$149.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C; 
&#x7C;Lawrence Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $136.00&#x7C;$133.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $135.00&#x7C;$130.00 &#x7C; 
&#x7C;Danielle Antalffy &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $148.00&#x7C;$146.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Abbott Laboratories's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Abbott Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>A Deep Dive into Abbott Laboratories's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Abbott Laboratories displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 84.1%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.1%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 11.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $145.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $145

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $135 to $137.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $137

U.S. stock futures rose on Thursday ahead of the long weekend, with Good Friday falling on April 18 and Easter Sunday on April 20. Futures of major benchmark indices were higher in premarket.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation">Federal Reserve</a> Chairman Jerome Powell dismissed the possibility of a &#8220;Fed put&#8221; in the near term while speaking in Chicago on Wednesday.
&#8220;We may find ourselves in the challenging scenario in which our dual-mandate goals are in tension. If that were to occur, we would consider how far the economy is from each goal, and the potentially different time horizons over which those respective gaps would be anticipated to close,&#8221; said Powell.
U.S. export restrictions on Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://benzinga.com/25/04/44844084/nvidias-h20-chip-ban-could-lead-to-manageable-sales-drop-bank-of-america-says">H20 GPUs</a> pulled the stock market down on Wednesday.
The 10-year Treasury bond yielded 4.32% and the two-year bond was at 3.82%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 86.4% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.75%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.83%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.66%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. The SPY was up 1.03% to $531.05, while the QQQ advanced 1.04% to $448.78, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
U.S. stocks closed sharply lower on Wednesday, driven by a significant sell-off in the semiconductor sector and broader tech weakness.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) experienced a steep decline, with Nvidia Corp. and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both falling approximately 7% following new export restrictions on Nvidia chips to China.
This news heavily impacted the information technology sector, which, along with consumer discretionary and communication services, recorded the largest losses. In contrast, energy stocks defied the overall downward trend, closing higher.
Among individual companies, Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported better-than-expected first-quarter results, and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) posted upbeat first-quarter adjusted EPS.
On the economic front, U.S. industrial production fell by 0.3% in March, slightly more than anticipated. However, U.S. retail sales surged 1.4% month-over-month in March, exceeding both the previous month&#8217;s gain and market expectations.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-3.07%</td>
<td>16,307.16</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.24%</td>
<td>5,275.70</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.73%</td>
<td>39,669.39</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.03%</td>
<td>1,863.48</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Scott Wren, the senior global market strategist at Wells Fargo, &#8220;current equity levels offer an attractive entry opportunity even with the bounce higher off the recent lows.&#8221;
Wren further emphasized the importance of having a &#8220;plan of action or at least be happy with where you currently stand,&#8221; regardless of individual perspectives on the implemented tariffs.
&#8220;Over the course of the last couple of weeks, we have seen the administration go from an aggressive reciprocal tariff strategy that involved meaningful universal tariffs on virtually all of our trading partners to a pause that suspends most reciprocal tariffs but leaves a 145% levy on imports from China,&#8221; Wren notes.
Despite the tariff uncertainty, Wren&#8217;s firm maintains a view that the U.S. economy was already heading for a slowdown in the first half of the year, even before the current trade strategies were implemented. &#8220;From our perspective, even before the current tariff strategies were deployed, our analysis suggested the economy was going to hit a bump in the road and slow in the first half of this year. That line of thought is still intact,&#8221; Wren states.
Wren also suggests a strategic shift in fixed income, advising investors to &#8220;move money from bonds, specifically the intermediate portion of the yield curve, into mid-cap U.S. equities in an effort to take advantage of the fall in stocks and the rally in bond prices (yields fell).&#8221;
Meanwhile, the <a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-currency-may-be-called-into-question-amid-tariff-turmoil">U.S. dollar is facing pressure</a>, with its &#8220;reserve currency&#8221; status. A recent study titled &#8216;Dollar Upheaval: This Time is Different&#8217; noted a 3.6% depreciation between April 4th and 14th, an unusual move as the dollar typically gains during global volatility.
This suggests a break from traditional market behavior, raising concerns that U.S. Treasuries lose their safe-haven appeal.
"If U.S. Treasuries are no longer viewed as the world's preferred safe asset, then the status of the dollar as the world's reserve currency may be called into question,&#8221; stated the note.
Investors are now <a href="https://www.benzinga.com/news/treasuries/25/04/44857989/gold-nears-3400-mark-experts-point-to-likely-correction-amid-bull-market-rates-will-drop-like-rock">flocking to Gold</a>, which has been hitting fresh highs as it trades above $3,300 per ounce. According to data shared by Charlie Bilello of Creative Planning, the inflation-adjusted gold prices were back at an all-time high, after 45 years, surpassing the prior peak from 1980.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It took 45 years to get there, but inflation-adjusted Gold prices are back at an all-time high, surpassing the prior peak from 1980. <a href="https://twitter.com/search?q=%24GOLD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOLD</a><a href="https://t.co/l5IYmkeySJ">https://t.co/l5IYmkeySJ</a> <a href="https://t.co/bXWisvrl3c">pic.twitter.com/bXWisvrl3c</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1912558536573268362?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Economist Mohamed El-Erian attributed the increasing price of gold to a gradual shift away from the U.S. dollar by some foreign central banks and other entities seeking diversification.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The price of gold registered another record high today, overcoming yet another periodic round of profit-taking by some tactical traders — this as it benefits from the tailwind of slow and steady diversification away from the dollar by some foreign central banks and others.<a href="https://twitter.com/hashtag/gold?src=hash&amp;ref_src=twsrc%5Etfw">#gold</a>… <a href="https://t.co/MKDnxZddv0">pic.twitter.com/MKDnxZddv0</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1912523089557987357?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday and Friday:
<ul>
<li>On Thursday, initial jobless claims data for the week ending April 12 and March&#8217;s housing starts, building permits, and April&#8217;s Philadelphia Fed manufacturing survey data will be released by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>On Friday, San Francisco Fed President Mary Daly will speak at 8:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell 0.64% in premarket on Thursday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $7.29 per share on revenue of $111.60 billion.</li>
</ul>
<ul>
<li>DR Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) rose 0.39% as Wall Street expects it to report earnings of $2.65 per share on revenue of $8.03 billion before the opening bell.</li>
</ul>
<ul>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) was up 1.38% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $5.72 per share on revenue of $10.52 billion.</li>
</ul>
<ul>
<li>FNB Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) was up 1.14% as it posted better-than-expected earnings for its first quarter on Wednesday.</li>
</ul>
<ul>
<li>Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) jumped 3.45% after reporting a 60% surge in its net profit for the first quarter, topping market expectations.</li>
</ul>
<ul>
<li>Rio Tinto Plc ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) climbed 1.68% after it announced the assessment of the low-carbon aluminum project in India along with AMG Metals &amp; Materials.</li>
</ul>
<ul>
<li>Woodside Energy Group Ltd. ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDS#NYSE">WDS</a>) advanced 2.73% after signing LNG supply agreements with Uniper.</li>
</ul>
<ul>
<li>BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) gained 1.08%, and Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) was 4.22% higher after BP completed loading the first cargo from the Greater Tortue Ahmeyim LNG project.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.02% to hover around $63.11 per barrel.
Gold Spot US Dollar declined 0.57% to hover around $3,324.20 per ounce. Its fresh record high stood at $3,357.81 per ounce. The U.S. Dollar Index spot was higher by 0.10% at the 99.4760 level.
Asian markets advanced on Wednesday, except China&#8217;s CSI 300 index. India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index ended higher. European markets were lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-currency-may-be-called-into-qu">Policy Push vs. Market Pull: Dollar Under Pressure As &#8216;Reserve Currency May Be Called Into Question&#8217; Amid Tariff Turmoil</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Commodities

Treasuries

US Stocks Likely To Open Higher Ahead Of Festive Weekend: 'Current Equity Levels Offer An Attractive Entry Opportunity'

The CNN Money Fear and Greed index showed a further increase in the overall fear level, while the index remained in the &#8220;Extreme Fear&#8221; zone on Wednesday.
U.S. stocks settled lower on Wednesday, with the Dow Jones index falling around 700 points during the session after Federal Reserve Chair Jerome Powell linked rising tariffs to higher inflation and slower growth, while making it clear the central bank has no intention of cushioning market losses.
Semiconductors were particularly hit hard following fresh export restrictions on Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips to China. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) fell sharply on Wednesday, with Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both down around 7%.
Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) posted better-than-expected first-quarter results on Wednesday. Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported upbeat first-quarter adjusted EPS results.
On the economic data front, U.S. industrial production declined by 0.3% in March compared to market estimates of a 0.2% fall. U.S. retail sales rose 1.4% month-over-month in March versus a 0.2% gain in the previous month and better than estimates of 1.3%.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, information technology, and communication services stocks recording the biggest losses on Wednesday. However, energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 700 points to 39,669.39 on Wednesday. The S&amp;P 500 fell 2.24% to 5,275.70, while the Nasdaq Composite dipped 3.07% to 16,307.16 during Wednesday's session.
Investors are awaiting earnings results from Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 14.4, the index remained in the &#8220;Extreme Fear&#8221; zone on Wednesday, versus a prior reading of 18.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based&nbsp;on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44836567/jim-cramer-nrg-energy-is-very-good-utility">Jim Cramer: NRG Up, Deluxe Out, Nvidia &#8216;You Have To Trim&#8217;</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Dips 3% Amid Plunge In Nvidia, AMD: Greed Index Remains In 'Extreme Fear' Zone

Risk sentiment took a sharp blow Wednesday afternoon after Federal Reserve Chair Jerome Powell linked rising tariffs to higher inflation and slower growth, while making it clear the central bank has no intention <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation">of cushioning market losses.</a>
In remarks at the Economic Club of Chicago, Powell said the inflationary effects of tariffs could be more persistent than previously thought, and warned that current policy uncertainty makes it difficult to gauge their full impact. 
Most notably for Wall Street, Powell addressed the notion of a so-called "Fed put"—the belief that the central bank would intervene if markets drop sharply—and offered a blunt response: "I'm going to say no."
That single line pushed traders to recalibrate expectations for any near-term monetary support.
<h3 class="wp-block-heading">Stocks Tumble As Chipmakers Extend Losses</h3>
By 3:15 p.m. ET, the S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – had dropped 3.1% to 5,230 points, while the Nasdaq 100 – tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) plunged 4.1% to 18,050, dragged down by the tech-heavy weighting of the index. 
The Dow Jones Industrial Average shed 838 points, or 2.1%, and the Russell 2000 small-cap index also fell 2.1%.
Nearly every sector turned red, with the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) nosediving 5%. Energy stocks were the sole exception, buoyed by higher crude prices and safe-haven commodity demand.
Semiconductors were particularly hard hit following fresh export restrictions on Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips to China. 
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) plummeted 6.8%, with Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) both down around 10%.
<h3 class="wp-block-heading">Gold Shines In Flight To Safety</h3>
As stocks tumbled, gold prices climbed, continuing their powerful 2025 rally. The precious metal hit new record highs, rising to over $2,350 an ounce, and is now up 26% year to date. 
With the Nasdaq 100 down 23% over the same period, gold has outperformed the tech index by nearly 50% in less than four months.
Gold's appeal has grown amid mounting inflation concerns, policy uncertainty, and geopolitical tension.
<h3 class="wp-block-heading">Powell: No Market Rescue This Time</h3>
Powell's refusal to endorse the "Fed put" marked a sharp shift in tone from the central bank's more accommodative stance in past downturns. While he acknowledged market volatility, he said both equity and bond markets were "functioning" and "orderly."
"Markets are struggling with a lot of uncertainty, and that means volatility," Powell said. "But having said that, markets are functioning."
The Fed chair emphasized that rate decisions will continue to focus on economic data, especially inflation and employment, and not on asset prices.
Top S&amp;P 500 Gainers:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>129.93</td>
<td>+2.94%</td>
</tr>
<tr>
<td>APA Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>)</td>
<td>15.27</td>
<td>+2.52%</td>
</tr>
<tr>
<td>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>29.21</td>
<td>+2.40%</td>
</tr>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>55.88</td>
<td>+2.37%</td>
</tr>
<tr>
<td>Diamondback Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>)</td>
<td>129.98</td>
<td>+2.23%</td>
</tr>
</tbody>
</table>
</figure>
Top S&amp;P 500 Losers:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Micro Devices Inc.</td>
<td>85.90</td>
<td>-9.86%</td>
</tr>
<tr>
<td>Nvidia Corp.</td>
<td>101.25</td>
<td>-9.76%</td>
</tr>
<tr>
<td>J.B. Hunt Transport Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NYSE">JBHT</a>)</td>
<td>123.21</td>
<td>-8.81%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>89.90</td>
<td>-8.63%</td>
</tr>
<tr>
<td>KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>622.99</td>
<td>-7.87%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44844084/nvidias-h20-chip-ban-could-lead-to-manageable-sales-drop-bank-of-america-says">Nvidia H20 Chip Ban Could Lead To &#8216;Manageable&#8217; Sales Drop, Bank Of America Says</a></li>
</ul>
Photo: Shutterstock

Stocks Sink As Powell Dismisses 'Fed Put' Safety Net, Gold Extends Massive Lead Over Nasdaq

U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip <a href="https://www.benzinga.com/topic/china">export restrictions to China.</a>
The U.S. government has barred Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from selling its H20 chips to China — a move that could wipe out an estimated $5.5 billion from the company's projected quarterly revenue. Nvidia shares slid nearly 7%.
Other chipmakers also felt the heat. Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 6% as its MI308 chips fall under the new licensing requirements.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) sank 3.4%, extending the sector&#8217;s losses. Adding to the drag, Dutch chip equipment giant ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) missed quarterly revenue estimates, sending its shares down 5%.
On the macro front, March retail sales surprised to the upside, rising 1.4% month-over-month — topping forecasts of 1.3% and marking the strongest monthly <a href="https://www.benzinga.com/25/04/44837237/march-retail-sales-post-highest-surge-in-over-two-years-as-us-consumers-anticipate-tariff-jitters">gain since January 2023.</a>
Meanwhile, the U.S. dollar saw renewed selling pressure, with the dollar index dipping back below 100. Treasury yields were little changed, with the 10-year yield holding steady near 4.33%.
Gold continued its stellar run, surging 2.5% to a fresh record high of $3,320 per ounce as demand for safe-haven assets remains robust.
In commodities, oil prices rebounded sharply, with WTI crude climbing 2% to $62 a barrel. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also edged up 1.3% to around $84,500.
All eyes are now on Fed Chair Jerome Powell, who is set to speak at the Economic Club of Chicago later this afternoon.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,318.86</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,872.38</td>
<td>-0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,340.12</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,501.22</td>
<td>-1.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 11:30 a.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.9% to $532.68.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $403.09.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;tanked 1.7% to $450.31.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $185.84.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.1%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.2%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>5.39%</td>
</tr>
<tr>
<td>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>4.33%</td>
</tr>
<tr>
<td>The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)</td>
<td>4.17%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>3.92%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>3.84%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>)</td>
<td>-8.40%</td>
</tr>
<tr>
<td>NVIDIA Corporation </td>
<td>-6.81%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>-5.81%</td>
</tr>
<tr>
<td>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>-4.77%</td>
</tr>
<tr>
<td>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>)</td>
<td>-4.71%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44832771/the-ball-is-in-chinas-court-trump-says-as-white-house-awaits-beijings-call-china-needs-to-make-a-deal-with-us">&#8216;The Ball Is In China&#8217;s Court&#8217;: Trump Says As White House Awaits Beijing&#8217;s Call — &#8216;China Needs To Make A Deal With Us&#8217;</a></li>
</ul>
Photo: Shutterstock

Asia

Sector ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

Select Sector SPDR-Consumer Discretionary

Nvidia Drags Wall Street Down, Gold Defies Gravity Ahead Of Powell Remarks: What's Driving Markets Wednesday?

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.
The Dow traded down 0.67% to 40,099.73 while the NASDAQ dipped 2.12% to 16,466.96. The S&amp;P 500 also fell, dropping, 1.27% to 5,327.95.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44836659/top-3-industrials-stocks-that-may-plunge-this-month">Top 3 Industrials Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Energy shares surged by 1.4% on Wednesday.
In trading on Wednesday, information technology shares fell by 3%.
Top Headline
Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter adjusted EPS results.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares shot up 70% to $3.54 after the company announced that it has secured an exclusive partnership with Mezzofy to become the sole distributor of its digital coupon platform and is targeting $2-4 million in annual recurring revenue.</li>
<li>Shares of Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>)got a boost, surging 70% to $2.3097.</li>
<li>iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares were also up, gaining 67% to $3.22 after the company announced it will be acquired by RadNet for a deal worth approximately $103 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares dropped 40% to $0.0249 as the company announced a 1-for-200 reverse stock split.</li>
<li>Shares of Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) were down 35% to $2.07. Ostin Technology Group announced the pricing of $5.0 million registered direct offering.</li>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) was down, falling 30% to $0.4006 after the company announced a 1-for-8 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $62.33 while gold traded up 2.6% at $3,323.10.
Silver traded up 1.7% to $32.860 on Wednesday, while copper rose 0.1% to $4.6310.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.7%, Germany's DAX 40 declined 0.4% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index slipped 0.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 1.01%, China's Shanghai Composite gaining 0.26%, Hong Kong's Gang Seng index dipping 1.91% and India's BSE Sensex gaining 0.4%.
Economics
<ul>
<li>U.S. industrial production declined by 0.3% in March compared to market estimates of a 0.2% fall.</li>
<li>U.S. retail sales rose 1.4% month-over-month in March versus a 0.2% gain in the previous month and better than estimates of 1.3%.</li>
<li>U.S. mortgage application volumes dipped by 8.5% from the previous week during the second week of April.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44838854/nvidia-to-160-here-are-10-top-analyst-forecasts-for-wednesday">Nvidia To $160? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Eurozone

BMRA

ICAD

SUNE

Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings

Abbott Laboratories<a target="_blank" href="https://www.benzinga.com/quote/ABT" rel="noreferrer noopener">&nbsp;</a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.40 billion</a>.
First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44835060/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance" rel="noreferrer noopener">testing-related sales</a>.
The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43174107/why-is-abbott-stock-trading-higher-on-thursday" rel="noreferrer noopener">guidance of $1.05-$1.09</a>.
&#8220;Once again, Abbott&#8217;s diversified business model delivered top-tier sales and EPS growth,&#8221; said&nbsp;Robert Ford, chairman and CEO of Abbott. &#8220;It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a>
Medical Device sales increased 9.9% to $4.89 billion with organic growth of 12.6%, led by Diabetes Care, Structural Heart, Heart Failure and Electrophysiology.
Several products, including FreeStyle Libre, Navitor, TriClip, Amplatzer&nbsp;Amulet, and AVEIR, contributed to the strong performance.
In Diabetes Care, sales of continuous glucose monitors were&nbsp;$1.7 billion&nbsp;and grew 18.3% on a reported basis and 21.6% on an organic basis.
Nutrition sales of $2.15 billion increased 3.8% on a reported basis and 6.8% on an organic basis in the first quarter.
In Pediatric Nutrition, global sales increased 3.2% on a reported basis and 4.9% on an organic basis.
In Adult Nutrition, global sales of $1.11 billion increased 4.4% on a reported basis and 8.7% on an organic basis, which was led by strong growth of Ensure and Glucerna.
Global Diagnostics sales of $2.05 billion decreased 7.2% on a reported basis, down 4.9% on an organic basis, or increased 0.5% when excluding COVID-19 testing-related sales.
The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in&nbsp;China impacted diagnostics sales growth.
COVID-19 testing-related sales were&nbsp;$84 million&nbsp;in the quarter, compared to&nbsp;$204 million&nbsp;a year ago.
Global Core Laboratory Diagnostics sales decreased 2.3% on a reported basis and increased 0.9% on an organic basis.
Abbott&#8217;s reported operating margin was 16.3% of sales, and adjusted operating margin of 21%, which reflects a 130 basis point increase year-over-year.
Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%.
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
In March, Abbott received European approval for the Volt PFA System for atrial fibrillation (AFib). The company will further expand its use in EU markets throughout the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44513547/abbott-receives-ce-mark-for-its-volt-pulsed-field-ablation-system-to-treat-patients-with-abnormal-" rel="noreferrer noopener">second half of the year</a>.
Last month,&nbsp;Abbott also announced late-breaking data from its TRILUMINATE&nbsp;trial that show the TriClip&nbsp;transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44560892/new-late-breaking-data-reinforce-benefits-of-abbotts-triclip-for-people-with-leaky-tricuspid-heart" rel="noreferrer noopener">severity of TR after two years</a>.
Price Action:&nbsp;ABT stock is up 5.02% at $132.55 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44836101/vale-q1-mixed-iron-ore-output-falls-4-amid-heavy-rains-copper-and-nickel-output-gains" target="_blank" rel="noreferrer noopener">Vale Q1 Iron Ore Output Falls 4.5% Amid Heavy Rains, Copper And Nickel Output Gain</a></li>
</ul>
Photo via Shutterstock

Guidance

Health Care

Movers

General

Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty

Press Releases

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

Abbott Hosts Conference Call for First-Quarter Earnings

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

CVKD

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Raymond James

Piper Sandler

RBC Capital

Wells Fargo

Morgan Stanley

Screenshot 2025-02-24 at 11.35.34 PM

Biotech

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2025-02-24 at 6.22.23 PM

DXCM

GCTK

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial

Screenshot 2024-12-03 at 7.43.04 PM

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

CNN 머니 공포·탐욕 지수는 수요일(16일) &#8216;극도의 공포&#8217; 영역에 머물렀지만 전반적인 공포 수준이 더 상승한 것으로 나타났다.
수요일 미국 증시는 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승 및 성장 둔화와 연결시키면서 연준이 시장 손실을 완화할 의사가 없음을 분명히 한 후 다우존스 지수가 장중 약 700포인트 하락하는 등 하락세로 마감했다.
반도체는 중국에 대한 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 칩의 새로운 수출 제한으로 인해 특히 큰 타격을 입었다. 아이셰어스 반도체 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>)는 수요일에 급락했으며, 엔비디아와 AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) 모두 약 7% 하락했다.
트래블러스 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)는 수요일에 예상보다 나은 1분기 실적을 발표했다. 애보트 래버러토리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 1분기 조정 주당순이익 실적이 예상치를 상회했다.
경제 데이터 측면에서, 미국의 산업생산은 3월에 0.3% 감소했으며, 이는 시장 예상치 0.2% 감소보다 큰 폭으로 하락한 것이다. 미국의 소매판매는 3월에 전월 대비 1.4% 상승했으며, 이는 이전 달의 0.2% 증가 및 1.3% 예상치보다 나은 결과였다.
S&amp;P 500 지수 대부분 섹터는 하락 마감으로 끝났으며, 소비자 선택, 정보 기술 및 커뮤니케이션 서비스 섹터가 가장 큰 손실을 입었다. 하지만 에너지 섹터는 전반적 시장 추세와 다르게 상승 마감했다.
다우존스는 수요일에 약 700포인트 하락하여 39,669.39포인트로 마감했다. S&amp;P 500은 2.24% 하락하여 5,275.70포인트, 나스닥 종합 지수는 3.07% 하락하여 16,307.16포인트에 도달했다.
투자자들은 오늘 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 그리고 DR호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 14.4이며 수요일에 "극도의 공포" 영역에 머물렀다. 이전 수치는 18.2였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엔비디아·AMD 급락으로 나스닥 3% 하락: 탐욕 지수는 '극도의 공포' 영역 유지

수요일(16일) 오후 제롬 파월 연준 의장이 관세 인상을 인플레이션 상승과 성장 둔화에 연결시키면서 연준이 <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation" target="_blank" rel="noopener">시장 손실을 완화할 의사가 없음</a>을 분명히 한 후 위험심리는 급격한 타격을 입었다.
파월 의장은 시카고 이코노믹 클럽 연설에서 관세의 인플레이션 효과가 이전에 생각했던 것보다 더 지속적일 수 있다고 말하며, 현재의 정책 불확실성으로 인해 관세의 전체 영향을 측정하기 어렵다고 경고했다.
특히 파월 의장은 월가에서 시장이 급락할 경우 연준이 개입할 것이라는 믿음인 이른바 &#8216;연준 풋&#8217;에 대해 언급하며 단호한 반응을 보였다. &#8220;나는 아니라고 말하겠다.&#8221;
이 한 마디에 트레이더들은 단기적인 통화정책 지원에 대한 기대치를 재조정했다.
<h3 class="wp-block-heading">주가 하락, 반도체 기업 손실 확대</h3>
수요일 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500 지수는 2.24% 하락한 5,275.70포인트로 마감했고, Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)가 추적하는 나스닥 100 지수는 기술주 중심 압박으로 인해 3.04% 하락한 18,257.64포인트로 마감했다.
다우존스 산업평균지수는 1.73% 하락했고, 838포인트, 즉 2.1% 하락했다. 소형주 중심 러셀 2000 지수도 2.03% 하락했다.
거의 모든 섹터가 하락으로 전환했으며 기술 선택 섹터 SPDR 펀드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 3.47% 급락했다. 에너지 주식은 유가 상승과 안전 자산 수요로 인해 유일한 예외였다.
반도체는 중국행 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 칩에 대한 새로운 수출 제한으로 인해 특히 큰 타격을 받았다.
iShares 반도체 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>)는 3.86% 하락했고 엔비디아는 6.87% 하락, AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)는 7.35% 하락했다.
<h3>안전자산 선호 속 금 상승</h3>
주식이 하락하는 동안 금값은 상승하며 2025년의 강력한 랠리를 이어갔다. 금은 온스당 2,350달러를 넘어서며 사상 최고치를 경신했고, 현재까지 26% 상승했다.
같은 기간 나스닥 100 지수가 23% 하락한 것과 비교하면, 금은 4개월 만에 기술 지수를 50% 가까이 상회하는 시장수익률을 기록했다.
인플레이션 우려, 정책 불확실성, 지정학적 긴장이 고조되는 가운데 금의 매력은 더욱 커지고 있다.
<h3>파월 &#8220;이번엔 시장 구조 없다&#8221;</h3>
파월 의장이 &#8216;연준 풋&#8217;을 지지하지 않은 것은 과거 경기 침체기에 중앙은행이 취했던 완화적인 자세에서 급격한 기조 전환을 의미한다. 그는 시장 변동성을 인정하면서도 주식과 채권 시장이 모두 "기능"하고 "질서"를 유지하고 있다고 말했다.
"시장은 많은 불확실성으로 어려움을 겪고 있으며, 이는 변동성을 의미한다. 하지만 그럼에도 불구하고 시장은 기능하고 있다."
파월 의장은 금리 결정은 자산 가격이 아닌 경제 데이터, 특히 인플레이션과 고용에 계속 초점을 맞출 것이라고 강조했다.
<h3>S&amp;P 500 상위 상승주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>종목</th>
<th>수요일 종가</th>
<th>변화 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>애보트 래버러토리스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>129.70</td>
<td>+2.76%</td>
</tr>
<tr>
<td>APA 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>)</td>
<td>15.37</td>
<td>+3.22%</td>
</tr>
<tr>
<td>데본 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>29.30</td>
<td>+2.70%</td>
</tr>
<tr>
<td>뉴몬트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>55.95</td>
<td>+2.56%</td>
</tr>
<tr>
<td>다이아몬드백 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>)</td>
<td>130.22</td>
<td>+2.42%</td>
</tr>
</tbody>
</table>
</figure>
<h3>S&amp;P 500 상위 하락주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>종목</th>
<th>수요일 종가</th>
<th>변화 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>88.29</td>
<td>-7.35%</td>
</tr>
<tr>
<td>엔비디아</td>
<td>104.49</td>
<td>-6.87%</td>
</tr>
<tr>
<td>JB 헌트 트랜스포트 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NYSE">JBHT</a>)</td>
<td>124.73</td>
<td>-7.68%</td>
</tr>
<tr>
<td>팔란티어 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>92.71</td>
<td>-5.78%</td>
</tr>
<tr>
<td>KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>642.19</td>
<td>-5.03%</td>
</tr>
</tbody>
</table>
</figure>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

파월 의장, '연준 풋' 기대 일축···미국 증시 하락, 금 상승세 확대

CNN 머니 공포·탐욕 지수는 전반적인 공포 수준이 증가했음을 보여 주었고, 지수는 화요일에 "극단적 공포" 영역에 머물렀다.
화요일(15일) 미국 증시는 하락세로 마감했고, 특히 다우존스 지수는 투자자들이 최근 실적 보고서를 평가하는 동안 세션 중 150포인트 이상 하락했다.
시티그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)은 1분기에 예상보다 나은 실적을 발표했다. 뱅크오브아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)도 1분기에 예상보다 강한 실적을 보고했다.
경제지표 측면에서, NY 엠파이어 스테이트 제조업 지수는 4월에 -20에서 -8.1로 상승했다.
미국 수출 가격은 3월에 변동이 없었고, 2월 수정치는 0.5% 상승이었다. 미국 수입 가격은 2025년 3월에 0.1% 하락했으며, 2월 수정치는 0.2% 상승이었다.
S&amp;P 500 지수 대부분의 섹터는 부정적인 마감으로 끝났으며 임의소비재, 헬스케어, 소비재 섹터가 화요일에 가장 큰 손실을 기록했다. 그러나 정보기술 및 부동산 주식은 전체 시장 추세에 반하여 상승세로 마감했다.
다우존스는 화요일에 약 156포인트 하락하여 40,368.96포인트로 마감했다. S&amp;P 500은 0.17% 하락하여 5,396.63포인트로로 마감했으며, 나스닥 종합지수는 화요일 세션 중 0.05% 하락하여 16,823.17포인트로 마감했다.
투자자들은 오늘 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 트래블러스 컴퍼니스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), 프로그레시브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>)의 분기 실적을 기다리고 있다.
<h3>CNN 비즈니스공포·탐욕 지수란?</h3>
공포·탐욕 지수 현재 18.4의 수치를 기록하고 있으며, 화요일에 "극단적 공포" 영역에 머물렀다. 이전 수치는 19.6이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

시티·뱅크오브아메리카 수익 예상치 상회, 다우 150포인트 이상 하락: 탐욕 지수 '극단적 공포' 영역 유지

수요일(16일) 미국 지수 선물이 하락세인 가운데, 오늘 투자자들이 주목할 만한 주식은 다음과 같다.
<ul>
<li>애보트 레버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): 수요일 개장 전 실적을 발표할 예정이다. 주당순이익 1.07달러와 매출 104억 달러를 예상하고 있다. 주가는 화요일 애프터마켓에서 0.01% 하락하여 126.21달러에 거래되었다.</li>
<li>트래블러스 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>): 수요일 개장 전 실적을 발표할 예정이다. 주당순이익 80센트, 매출 108억 2천만 달러를 예상하고 있다. 주가는 애프터마켓에서 0.1% 상승하여 249.85달러에 거래되었다.</li>
<li>JB헌트 트랜스포트 서비스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>): 1분기 이익이 7.6% 감소했다고 보고했다. 회사는 분기 매출액이 29억 2천만 달러로 시장 예상치 29억 달러를 초과했다. 주가는 화요일 애프터마켓에서 6% 하락한 126.97달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>ASML 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): 1분기 총 순매출이 77억 유로, 순이익이 24억 유로라고 발표했다. 회사는 2분기 총 순매출이 72억 유로에서 77억 유로가 될 것으로 전망했다. 주가는 화요일 애프터마켓에서 1.5% 하락한 673.00달러에 거래되었다.</li>
<li>프로그레시브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>): 수요일 개장 전 실적을 발표할 예정이다. 주당순이이익 4.81달러, 매출 216억 3천만 달러로 예상된다. 주가는 화요일 애프터마켓에서 0.3% 상승한 277.00달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 주목해야 할 주식: 애보트, 트래블러스, JB헌트 트랜스포트, ASML 및 프로그레시브

수요일(22일) 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 4분기 매출이 전년 동기 대비 7.2% 증가한 109억 7,000만 달러로 <a href="https://www.benzinga.com/25/01/43131874/abbott-q4-sales-fall-short-of-estimates-issues-q1-profit-guidance-lower-than-street-view" target="_blank" rel="noopener">컨센서스인 110억 1,000만</a> 달러에 미치지 못했다고 발표했다.
또한 기본 사업의 유기적 매출 성장률은 8.8%였다. 비교하자면 코로나19 테스트 관련 매출을 제외한 유기적 매출 성장률은 10.1%였다.
스티펠의 애널리스트 릭 와이즈(Rick Wise)는 애보트의 2024년 4분기 실적과 2025년 전망에 대해 긍정적인 전망을 내놓았다. 그는 당뇨병 관리 및 구조적 심장 부문에서 강력한 모멘텀이 있으며, 이는 의료기기 부문의 두 자릿수 성장과 회사 전체의 높은 한 자릿수 성장을 견인할 것으로 예상하고 있다.
애보트 CEO인 로버트 포드(Robert Ford)는 당뇨병 관리 부문의 주요 성장 기회에 대해 설명했다. 여기에는 인슐린을 많이 사용하는 환자들의 연속 혈당 측정기(CGM) 사용 증가, Libre 시스템의 인슐린 펌프 연결성을 통한 시장 점유율 확대, Lingo CGM을 통한 소비자 시장 공략 등이 포함된다.
또한 애보트는 내부 비용 이니셔티브의 성공을 반영하여 150bp의 영업 마진 개선을 달성할 것으로 예상하고 있다. 이를 통해 장기적으로 두 자릿수 퍼센트의 주당순이익 성장을 유지할 수 있을 것으로 예상한다.
릭 와이즈는 애보트의 사업 부문이 보다 독특한 제품을 제공하고 있으며, 코로나19 이후 회복세가 지속됨에 따라 의료 기술 부문에서 강력한 성장세를 보일 것으로 전망했다. 이들은 향후 몇 년 동안 더 나은 실행, 프랜차이즈 전반에 걸친 주요 제품 출시, 현금 창출과 부채 감소에 더욱 집중함으로써 애보트의 매출과 이익이 개선될 것으로 예상한다.
스티펠은 애보트의 목표주가를 기존 130달러에서 135달러로 <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noopener">상향 조정하고 매수 의견을 유지했다.</a>
한편 파이퍼 샌들러는 애보트의 4분기 보고서가 긍정적이었으며, 새해에도 탄탄한 실적을 거둘 것으로 예상했다. 애널리스트인 애덤 매더(Adam Maeder) 주가에 대해 건설적인 시각을 유지하고 있으며, 대형주 의료기술(MedTech) 분야에서 GARP에 노출될 수 있는 가장 좋은 방법은 애보트 주식이라고 생각한다. 파이퍼 샌들러는 133달러 목표주가와 비중확대 의견을 유지했다.
ABT 주가 움직임: 목요일 애보트 래버러토리스 주가는 4.62% 상승한 123.22달러로 마감했다.
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Analyst Color

애보트 래버러토리스, 목요일 주가 5% 가까이 오른 이유는?

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가적으로 개선되었음을 보여주었지만, 수요일(22일) 여전히 &#8220;공포&#8221; 영역에 머물렀다.
미국 주식은 수요일에 상승 마감하였으며, S&amp;P 500 지수는 장중에 사상 최고가로 상승했다.
넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)는 화요일에 예상치를 크게 상회한 4분기 재무 실적을 발표했다. 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>)도 예상보다 좋은 2분기 재무 실적을 발표했다. 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 4분기 매출이 109억 7천만 달러로 전년 대비 7.2% 증가했지만, 컨센서스인 110억 1천만 달러를 하회했다고 발표했다.
경제지표 측면에서, 미국의 주택담보대출 신청건수는 1월 17일 주간에 전주 대비 0.1% 증가했다.
S&amp;P 500 지수 대부분의 섹터가 부정적인 흐름으로 마감되었고 특히 유틸리티, 부동산, 에너지 섹터가 하락했다. 그러나 정보기술과 통신서비스 섹터는 상승 마감했다.
다우존스 지수는 수요일에 약 131포인트 상승하여 44,156.73포인트로 마감, S&amp;P 500은 0.61% 상승하여 6,086.37포인트로 마감했다. 나스닥 종합지수는 1.28% 상승하여 20,009.34포인트로 마감했다.
투자자들은 오늘 GE 에어로스페이스NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), 아메리칸항공(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), 유니온 퍼시픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 43.3을 기록하고 있고 수요일에 여전히 &#8220;공포&#8221; 영역에 머물렀다. 이전 수치는 41.5였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

S&P 500 사상 최고치 경신, 넷플릭스의 강력한 실적: 투자 심리 개선되었지만 탐욕 지수는 계속 '공포' 영역에

S&amp;P 500이 수요일에 6,100포인트를 잠시 넘기며 새로운 사상 최고치를 기록했다. 이는 강력한 기업 실적과 도널드 트럼프 대통령의 5,000억 달러 규모의 인공지능(AI) 투자 계획인 &#8220;<a href="https://www.benzinga.com/25/01/43139410/softbanks-role-in-500-billion-stargate-ai-venture-seen-as-major-growth-driver-analyst-says">AI 스타게이트</a>&#8220;의 발표로 월가가 긍정적으로 반응한 결과이다.
이 프로젝트는 미국의 AI 인프라를 혁신하는 것을 목표로 하며, 이미 예상보다 강한 4분기 실적과 올해 후반에 연방준비제도(연준)의 금리 인하 기대감이 높아진 시장에 추가적인 활력을 불어넣었다.
대형 기술 주식과 반도체 기업들이 이끌면서 S&amp;P 500 — SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 지수 — 는 최근 7거래일 중 6거래일 동안 상승했다.
수요일 정오까지 S&amp;P 500은 6,100.4포인트에 도달하여 12월 6일에 세운 이전 기록인 6,099포인트를 간신히 넘겼다.
자세한 내용 보기: <a href="https://www.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">S&amp;P 500 SPY ETF의 생일을 축하! SPY 출시 시 1,000달러를 투자했다면 현재 얼마나 되었을까?</a>
<h3 class="wp-block-heading">AI 스타게이트: AI 인프라에 대한 게임 체인저 투자</h3>
트럼프는 1월 21일 AI 스타게이트를 발표했다. 이 합작 투자에는 샘 올트먼이 이끄는 오픈AI, 손 마사요시이 지원하는 소프트뱅크 및 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 함께 참여하여 차세대 AI 인프라를 구축하는 프로젝트이다.
이 프로젝트는 향후 4년 동안 최대 5,000억 달러를 투자하여 미국 전역에 대규모 AI 데이터 센터를 구축하는 것을 목표로 하며, 초기 단계에는 1,000억 달러가 투자된다.
트럼프는 이 이니셔티브를 &#8220;미국의 잠재력에 대한 신뢰 선언&#8221;으로 칭하며, AI 기술의 미래를 미국 국경 내에 두는 것의 중요성을 강조했다.
AI 스타게이트는 거의 즉시 10만 개의 일자리를 창출할 것으로 예상되며, 이는 경제 성장에 대한 낙관론을 더욱 강화한다.
<h3 class="wp-block-heading">실적 강세가 시장 낙관론을 자극</h3>
AI에 대한 기대감이 헤드라인을 장식한 가운데, 강력한 기업 실적 시즌이 시장 상승의 기초를 마련했다.
팩트셋(FactSet)에 따르면, 1월 17일 기준으로, 4분기 실적을 발표한 S&amp;P 500 기업 중 81%가 월가의 이익 예상을 초과했으며, 64%가 매출 예상치를 초과한 것으로 나타났다.
이번 주 실적을 발표한 대형 기업들 — 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), 찰스 슈왑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), 프로로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) 및 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) — 모두 예상을 초과하여 발표되었으며, 이는 투자자들의 미국 기업에 대한 신뢰를 강화했다.
&#8220;S&amp;P 500의 선행 이익률은 2025년 1월 18일 주에 기록적인 13.6%에 달했으며, 이는 1년 전의 12.7%에서 0.9포인트 증가한 수치이다&#8221;라고 베테랑 투자자인 에드 야데니(Ed Yardeni)가 수요일 노트에서 밝혔다.
&#8220;트럼프 행정부가 큰 재정적 역풍에 직면하더라도 기업의 수익성은 계속해서 개선될 것이다.&#8221;
<h2 class="wp-block-heading">기술 대기업들이 시장을 상승</h2>
수요일의 상승은 이른바 &#8220;매그니피센트 7&#8221; 주식들이 중심에 있었으며, Roundhill Magnificent Seven ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>)가 1.53% 상승했다.
마이크로소프트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>)는 4.13% 급등했으며, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 4.43% 상승 마감하여 AI 경쟁에서의 지배력을 강화했다. 반도체 주식들은 AI 관련 인프라 수요 증가에 대한 투자자들의 베팅으로 특히 강한 상승세를 보였다.
소프트뱅크가 소유한 반도체 설계 회사 Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 15.93% 급등하며 2024년 2월 이후 가장 큰 단일 일간 상승률을 기록했다.
소프트뱅크의 2024년 연례 보고서에서는 Arm이 &#8220;인공지능 초지능(AI Super Intelligence)을 위한 기초 기술&#8221;을 제공한다고 설명했으며, 이는 AI 스타게이트가 구체화됨에 따라 점점 더 관련성이 높아 보인다.
<h3 class="wp-block-heading">S&amp;P 500 사상 최고가를 이끈 6종목</h3>
수요일에 시장의 급등을 이끈 것은 몇몇 회사들이었다.
엔비디아와 마이크로소프트는 S&amp;P 500의 상승에 각각 53bp(베이시스포인트)를 기여했으며, 넷플릭스, 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) 및 오라클은 함께 18bp를 추가했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>종목명</th>
<th>가격</th>
<th>S&amp;P 500 내 비중</th>
<th>1일 %변화</th>
<th>S&amp;P 500 기여도</th>
</tr>
</thead>
<tbody>
<tr>
<td>엔비디아</td>
<td>$1,472.46</td>
<td>6.51%</td>
<td>4.55%</td>
<td>+29bp</td>
</tr>
<tr>
<td>마이크로소프트</td>
<td>$445.37</td>
<td>6.27%</td>
<td>3.94%</td>
<td>+24bp</td>
</tr>
<tr>
<td>넷플릭스</td>
<td>$952.64</td>
<td>0.72%</td>
<td>9.54%</td>
<td>+6bp</td>
</tr>
<tr>
<td>아마존닷컴</td>
<td>$233.46</td>
<td>4.10%</td>
<td>1.19%</td>
<td>+5bp</td>
</tr>
<tr>
<td>메타 플랫폼스</td>
<td>$626.13</td>
<td>2.65%</td>
<td>1.57%</td>
<td>+4bp</td>
</tr>
<tr>
<td>오라클</td>
<td>$184.92</td>
<td>0.51%</td>
<td>7.15%</td>
<td>+3bp</td>
</tr>
</tbody>
</table>
</figure>
지금 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/indices/%EB%8F%85%EC%A0%90-sp-500%EC%9D%B4-%ED%8A%B8%EB%9F%BC%ED%94%84%EC%9D%98-%EB%91%90%EB%B2%88%EC%A7%B8-%EC%9E%84%EA%B8%B0-%EB%8F%99%EC%95%88-%EC%B2%AB%EB%B2%88%EC%A7%B8%EC%99%80-%EA%B0%99%EC%9D%80/" target="_blank" rel="noopener">S&amp;P 500이 트럼프의 첫 임기 동안 기록한 큰 상승폭을 두 번째로 반복할 수 있을까요? 독자들이 말하는 이 수익률 범위가 가장 가능성이 높습니다&#8230;</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AMZN

MAGS

MSFT

ORCL

SCHW

S&P 500이 6,100의 최고가를 경신: 강력한 기업 실적, 트럼프의 AI 베팅이 상승을 격려

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 개선된 것으로 나타냈지만, 화요일(21일)에도 여전히 &#8216;공포&#8217; 영역에 머물렀다.
화요일 미국 증시는 도널드 트럼프가 1월 20일 제47대 미국 대통령으로 취임한 이후 투자자들이 국내 친화적인 정책에 베팅하면서 다우존스 지수가 장중 500포인트 이상 상승하는 등 상승세로 마감했다.
3가지 주요 지수 모두 2025년의 첫 주간 상승을 기록했다. 지난주 다우존스 지수는 3.7%, S&amp;P 500 지수는 2.9% 상승했다. 한편, 나스닥 지수는 한 주 동안 2.5% 상승하며 12월 이후 가장 강력한 주간 실적을 기록했다.
DR호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)은 예상보다 양호한 1분기 실적을 발표했다. 3M(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)도 2024년 4분기 호실적을 발표하고 2025년 긍정적 가이던스를 제시했다.
화요일에는 산업, 부동산, 헬스케어 섹터가 상승세를 기록하는 등 S&amp;P 500 지수 대부분의 섹터가 상승세로 마감했다. 그러나 에너지주는 전체 시장 추세를 역행하며 하락세로 마감했다.
화요일 다우존스 지수는 약 538포인트 상승한 44,025.81포인트, S&amp;P 500 지수는 0.88% 상승한 6,049.24포인트, 나스닥 종합지수는 0.64% 상승한 19,756.78포인트로 마감했다.
투자자들은 오늘 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 화요일 현재 40.8을 기록하며 &#8220;공포&#8221; 영역에 머물렀다. 이전 수치는 37.6이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Abbott Laboratories

뉴스

에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

목요일, 4월 17, 2025

수요일, 4월 16, 2025

금요일, 1월 24, 2025

목요일, 1월 23, 2025

수요일, 1월 22, 2025

월요일, 10월 14, 2024

목요일, 7월 18, 2024

화요일, 6월 04, 2024

수요일, 4월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌